IIM
MLYS icon

INTECH Investment Management’s Mineralys Therapeutics MLYS Stock Holding History

INTECH Investment Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
11,385
+126
+1% +$3.46K ﹤0.01% 1573
2026
Q1 		$305K Sell
11,259
-5,464
-33% -$160K ﹤0.01% 1569
2025
Q4 		$607K Buy
+16,723
New +$671K 0.01% 1398
2025
Q3 		– Sell
-21,629
Closed -$293K – 2472
2025
Q2 		$293K Buy
+21,629
New +$313K ﹤0.01% 1875

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

INTECH Investment Management's MLYS Position: Q2 2026 in Review

INTECH Investment Management increased its Mineralys Therapeutics (MLYS) stake by 1.1% in Q2 2026, buying an estimated $3.46K and bringing the position to 11,385 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

INTECH Investment Management first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $607K in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • INTECH Investment Management held 11,385 shares of Mineralys Therapeutics worth $307K as of Q2 2026.
  • INTECH Investment Management bought 126 Mineralys Therapeutics shares in Q2 2026, an estimated $3.46K.
  • Mineralys Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1573 holding.
  • INTECH Investment Management first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • INTECH Investment Management's Mineralys Therapeutics position peaked at $607K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.